DK3806855T5 - GLP-1-receptoragonister og anvendelser deraf - Google Patents

GLP-1-receptoragonister og anvendelser deraf Download PDF

Info

Publication number
DK3806855T5
DK3806855T5 DK19759027.6T DK19759027T DK3806855T5 DK 3806855 T5 DK3806855 T5 DK 3806855T5 DK 19759027 T DK19759027 T DK 19759027T DK 3806855 T5 DK3806855 T5 DK 3806855T5
Authority
DK
Denmark
Prior art keywords
glp
receptor agonists
agonists
receptor
Prior art date
Application number
DK19759027.6T
Other languages
English (en)
Other versions
DK3806855T3 (da
Inventor
Gary Erik Aspnes
Scott W Bagley
Edward L Conn
John M Curto
David James Edmonds
Mark E Flanagan
Kentaro Futatsugi
David A Griffith
Kim Huard
Chris Limberakis
Alan M Mathiowetz
David W Piotrowski
Roger B Ruggeri
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of DK3806855T3 publication Critical patent/DK3806855T3/da
Application granted granted Critical
Publication of DK3806855T5 publication Critical patent/DK3806855T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
DK19759027.6T 2018-06-15 2019-06-13 GLP-1-receptoragonister og anvendelser deraf DK3806855T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685656P 2018-06-15 2018-06-15
PCT/IB2019/054961 WO2019239371A1 (en) 2018-06-15 2019-06-13 Glp-1 receptor agonists and uses thereof

Publications (2)

Publication Number Publication Date
DK3806855T3 DK3806855T3 (da) 2023-04-24
DK3806855T5 true DK3806855T5 (da) 2023-05-22

Family

ID=67766191

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19759027.6T DK3806855T5 (da) 2018-06-15 2019-06-13 GLP-1-receptoragonister og anvendelser deraf

Country Status (21)

Country Link
US (3) US11858916B2 (da)
EP (1) EP3806855B1 (da)
JP (1) JP7053900B2 (da)
KR (1) KR102538572B1 (da)
CN (1) CN112566637B (da)
AU (1) AU2019285570B2 (da)
BR (1) BR112020024956A2 (da)
CA (1) CA3103051C (da)
DK (1) DK3806855T5 (da)
ES (1) ES2943510T3 (da)
FI (1) FI3806855T3 (da)
HU (1) HUE061888T2 (da)
IL (1) IL279224B2 (da)
MX (1) MX394736B (da)
PL (1) PL3806855T3 (da)
PT (1) PT3806855T (da)
RU (1) RU2765721C1 (da)
SG (1) SG11202011704XA (da)
SI (1) SI3806855T1 (da)
WO (1) WO2019239371A1 (da)
ZA (1) ZA202007304B (da)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3806855T5 (da) * 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
EP3953344A4 (en) * 2019-04-12 2023-08-09 Qilu Regor Therapeutics Inc. GLP-IR AGONISTS AND THEIR USES
TWI751585B (zh) 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
WO2021018023A1 (zh) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 小分子glp-1受体调节剂
EP4048664A1 (en) 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
KR102635237B1 (ko) 2019-12-10 2024-02-13 일라이 릴리 앤드 캄파니 옥세탄-2-일메탄아민의 제조를 위한 방법 및 중간체
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
HRP20241159T1 (hr) 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
JP7836762B2 (ja) * 2020-02-13 2026-03-27 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
IL296336A (en) * 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
CN113493447B (zh) * 2020-04-03 2024-06-11 轩竹(北京)医药科技有限公司 Glp-1受体激动剂
TW202144340A (zh) * 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
IL296423A (en) * 2020-04-22 2022-11-01 Anima Biotech Inc Collagen 1 translation inhibitors and methods of use thereof
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
MX2022015026A (es) * 2020-06-04 2023-01-04 Hangzhou Sciwind Biosciences Co Ltd Compuesto heteroaromatico de imidazol de cinco miembros y uso del mismo.
CN115697338B (zh) * 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN115916772B (zh) * 2020-06-19 2025-01-14 江苏恒瑞医药股份有限公司 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
CN113831337B (zh) * 2020-06-24 2023-03-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CA3192601A1 (en) * 2020-08-21 2022-02-24 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4204415A4 (en) * 2020-08-28 2025-03-26 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CN116368140A (zh) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022068772A1 (zh) * 2020-09-29 2022-04-07 深圳信立泰药业股份有限公司 一种苯并咪唑类衍生物及其制备方法和医药用途
US20240083886A1 (en) * 2020-10-13 2024-03-14 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4229050A4 (en) * 2020-10-13 2024-12-11 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN116710446B (zh) * 2020-10-14 2024-10-18 上海齐鲁锐格医药研发有限公司 Glp-1r激动剂的晶型及其用途
CN114478497B (zh) * 2020-11-12 2023-10-20 杭州中美华东制药有限公司 芳基烷基酸类glp-1受体激动剂及其用途
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
MX2023006186A (es) 2020-11-27 2023-08-07 Shenzhen Salubris Pharm Co Ltd Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo.
CN114591308B (zh) * 2020-12-03 2024-03-08 苏州闻泰医药科技有限公司 一类glp-1r受体激动剂化合物及其用途
CN114805336B (zh) * 2021-01-20 2026-04-14 江苏恒瑞医药股份有限公司 稠合咪唑类化合物、其制备方法及其在医药上的应用
WO2022184849A1 (en) 2021-03-04 2022-09-09 Les Laboratoires Servier Glp-1r agonists, uses and pharmaceutical compositions thereof
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
WO2022216094A1 (ko) * 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
CN117279904A (zh) * 2021-04-08 2023-12-22 株式会社Lg化学 Glp-1受体激动剂、包含其的药物组合物及其制备方法
IL306110A (en) 2021-04-21 2023-11-01 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
CN117715906A (zh) * 2021-07-21 2024-03-15 和博医药有限公司 胰高血糖素样肽-1受体调节剂及其用途
CN113480534B (zh) * 2021-07-23 2022-05-13 广州必贝特医药股份有限公司 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用
WO2023011395A1 (zh) * 2021-08-02 2023-02-09 深圳信立泰药业股份有限公司 Glp-1r激动剂化合物的盐及其制备方法和医药用途
WO2023011539A1 (zh) * 2021-08-04 2023-02-09 上海翰森生物医药科技有限公司 环烯类衍生物调节剂、其制备方法和应用
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
WO2023057414A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US20250115612A1 (en) 2021-10-05 2025-04-10 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators
MX2024004131A (es) 2021-10-05 2024-04-22 Astrazeneca Ab Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1.
TWI843243B (zh) * 2021-10-22 2024-05-21 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
WO2023098852A1 (en) * 2021-12-03 2023-06-08 Hangzhou Sciwind Biosciences Co., Ltd. Crystal forms of thienoimidazole compound and preparation method thereof
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023111144A1 (en) 2021-12-16 2023-06-22 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
WO2023130878A1 (zh) * 2022-01-10 2023-07-13 海思科医药集团股份有限公司 一种glp-1激动剂盐及其晶型及在医药上的应用
EP4469444A4 (en) * 2022-01-24 2026-01-07 Gasherbrum Bio Inc GLP-1 HETEROCYCLIC AGONISTS
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
AU2023232184A1 (en) 2022-03-08 2024-09-26 Guangzhou Apichope Pharmaceutical Co., Ltd. Benzo bicyclic compound, and preparation method and application thereof
CN120289354A (zh) * 2022-07-18 2025-07-11 厦门市博瑞来医药科技有限公司 五元并六元化合物、其中间体、制备方法、组合物和应用
EP4562006A1 (en) * 2022-07-27 2025-06-04 Carmot Therapeutics, Inc. N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
EP4592285A1 (en) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Fused ring compound having glp-1 receptor agonist effect
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
KR20250085816A (ko) 2022-11-16 2025-06-12 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드 1 수용체 효능제
TW202440556A (zh) * 2022-12-13 2024-10-16 中國大陸商杭州中美華東製藥有限公司 鹽型的glp-1受體激動劑、其晶型和製備方法及其藥物組合物和用途
JP2026500865A (ja) 2023-01-13 2026-01-08 中国科学院上海薬物研究所 Ｇｌｐ－１受容体アゴニストとして使用される４－アルコキシベンゾイミダゾール－６－カルボン酸誘導体
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
EP4695226A1 (en) 2023-04-14 2026-02-18 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
AR133240A1 (es) 2023-07-13 2025-09-10 Aconcagua Bio Inc Compuestos, composiciones y métodos
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
WO2025104668A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
TW202539633A (zh) 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025208093A1 (en) * 2024-03-28 2025-10-02 Gila Therapeutics, Inc. Compositions and methods for treating metabolic diseases with topical-lingual receptor agonists
US20250326741A1 (en) 2024-04-22 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026013531A1 (en) 2024-07-10 2026-01-15 Pfizer Inc. Spiro[2.5]octane compounds
WO2026033382A1 (en) 2024-08-07 2026-02-12 Pfizer Inc. Heterocyclic glp-1r modulators
WO2026042018A1 (en) 2024-08-21 2026-02-26 Pfizer Inc. 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-d-prolyl)amino]cyclohexyl}benzoic acid derivatives as gipr antagonists for the treatment of diabetes
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026078617A1 (en) 2024-10-11 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078671A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic compounds as glucose-dependent insulinotropic polypeptide receptor antagonists
WO2026078670A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists
WO2026078673A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078672A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof
WO2026078674A1 (en) 2024-10-13 2026-04-16 Pfizer Inc. Heterocyclic derivatives as glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US20040127504A1 (en) * 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
WO2005063761A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
CA2646755A1 (en) 2006-03-31 2007-10-11 Astrazeneca Ab Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
WO2011143365A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2014044738A1 (en) * 2012-09-21 2014-03-27 Sanofi Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators
KR102314286B1 (ko) * 2016-12-16 2021-10-21 화이자 인코포레이티드 Glp-1 수용체 작용제 및 이의 용도
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
DK3806855T5 (da) * 2018-06-15 2023-05-22 Pfizer GLP-1-receptoragonister og anvendelser deraf
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations

Also Published As

Publication number Publication date
US20250270196A1 (en) 2025-08-28
SG11202011704XA (en) 2020-12-30
BR112020024956A2 (pt) 2021-03-09
EP3806855A1 (en) 2021-04-21
US20210332034A1 (en) 2021-10-28
KR20210020095A (ko) 2021-02-23
NZ770628A (en) 2024-09-27
PL3806855T3 (pl) 2023-07-24
CN112566637A (zh) 2021-03-26
CA3103051C (en) 2023-01-17
JP2021528394A (ja) 2021-10-21
IL279224B2 (en) 2023-07-01
US20240132483A1 (en) 2024-04-25
DK3806855T3 (da) 2023-04-24
RU2765721C1 (ru) 2022-02-02
IL279224B1 (en) 2023-03-01
PT3806855T (pt) 2023-05-03
MX2020013624A (es) 2022-08-11
EP3806855B1 (en) 2023-03-01
ZA202007304B (en) 2023-11-29
CN112566637B (zh) 2023-11-14
HUE061888T2 (hu) 2023-08-28
FI3806855T3 (fi) 2023-05-04
MX394736B (es) 2025-03-24
ES2943510T3 (es) 2023-06-13
CA3103051A1 (en) 2019-12-19
US12331041B2 (en) 2025-06-17
AU2019285570B2 (en) 2022-03-24
AU2019285570A1 (en) 2020-12-17
US11858916B2 (en) 2024-01-02
SI3806855T1 (sl) 2023-06-30
KR102538572B1 (ko) 2023-06-01
IL279224A (en) 2021-01-31
WO2019239371A1 (en) 2019-12-19
JP7053900B2 (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
DK3806855T3 (da) GLP-1-receptoragonister og anvendelser deraf
DK3806955T3 (da) GLP-1-receptoragonister og anvendelser deraf
DK4058445T3 (da) Glp-1-receptoragonist og anvendelse deraf
DK3555064T5 (da) GLP-1 receptoragonister og anvendelser deraf
DK3596053T3 (da) Farnesoid-x-receptoragonister og anvendelser deraf
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
IL287128A (en) Glp-1r agonists and uses thereof
EP4069686C0 (en) GLP-1 RECEPTOR AGONIST
IL280290A (en) Il2 agonists
DK3609888T3 (da) Farnesoid x-receptor-agonister og anvendelser deraf
DK3762380T3 (da) Phenylpyrrolidinon-formylpeptid-2-receptoragonister
DK3743418T3 (da) Chemokinreceptormodulatorer og anvendelser deraf
IL304574A (en) Glucagon-like peptide 1 receptor agonists and uses thereof
DK3350165T3 (da) Farnesoid-X-receptoragonister og anvendelser deraf
EP3852737A4 (en) Farnesoid x receptor agonists and uses thereof
IL281475A (en) Farnesoid x receptor agonists and uses thereof
EP3565573A4 (en) PAC1 RECEIVER AGONISTS (MAXCAPS) AND THEIR USES
EP3440051A4 (en) AGROISTS OF NEUROPEPTIDE RECEPTOR (NPSR)
DK3406264T3 (da) Sammensætning omfattende GLP-1-receptoragonist og glucagonreceptoragonist og anvendelse deraf
MA52882A (fr) Agonistes du récepteur glp-1 et leurs utilisations